Q2 2023 Earnings Estimate for Disc Medicine Opco Inc (NASDAQ:IRON) Issued By Wedbush

Disc Medicine Opco Inc (NASDAQ:IRON – Get Rating) – Wedbush dropped their Q2 2023 earnings per share (EPS) estimates for Disc Medicine Opco in a research report issued to clients and investors on Monday, May 15th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($1.23) for the quarter, down from their previous estimate of ($0.71). The consensus estimate for Disc Medicine Opco’s current full-year earnings is ($3.32) per share. Wedbush also issued estimates for Disc Medicine Opco’s Q3 2023 earnings at ($1.34) EPS, Q4 2023 earnings at ($1.19) EPS, FY2023 earnings at ($4.96) EPS, Q1 2024 earnings at ($1.32) EPS, Q2 2024 earnings at ($1.45) EPS, Q3 2024 earnings at ($1.31) EPS, Q4 2024 earnings at ($1.39) EPS and FY2024 earnings at ($5.47) EPS.

IRON has been the subject of several other reports. Stifel Nicolaus started coverage on Disc Medicine Opco in a report on Thursday, April 20th. They set a “buy” rating and a $37.00 price objective for the company. Morgan Stanley initiated coverage on Disc Medicine Opco in a report on Thursday, April 20th. They set an “overweight” rating and a $37.00 price objective for the company. SVB Leerink restated an “outperform” rating and set a $36.00 target price on shares of Disc Medicine Opco in a report on Tuesday, February 28th. Raymond James initiated coverage on Disc Medicine Opco in a report on Tuesday. They set an “outperform” rating and a $50.00 target price on the stock. Finally, Cantor Fitzgerald initiated coverage on Disc Medicine Opco in a report on Friday, April 28th. They set an “overweight” rating and a $45.00 target price on the stock. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $38.88.

Disc Medicine Opco Stock Down 1.4 %

Shares of NASDAQ:IRON opened at $33.58 on Thursday. Disc Medicine Opco has a 1 year low of $11.80 and a 1 year high of $35.03. The stock’s fifty day moving average price is $26.40.

Disc Medicine Opco (NASDAQ:IRON – Get Rating) last announced its quarterly earnings data on Monday, May 15th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.53).

Institutional Investors Weigh In On Disc Medicine Opco

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE grew its position in shares of Disc Medicine Opco by 134,000.0% in the first quarter. Bank of America Corp DE now owns 2,682 shares of the company’s stock valued at $57,000 after purchasing an additional 2,680 shares during the last quarter. Citigroup Inc. acquired a new stake in shares of Disc Medicine Opco in the fourth quarter valued at about $101,000. Barclays PLC grew its position in shares of Disc Medicine Opco by 2,709.5% in the first quarter. Barclays PLC now owns 5,619 shares of the company’s stock valued at $119,000 after purchasing an additional 5,419 shares during the last quarter. UBS Group AG acquired a new stake in shares of Disc Medicine Opco in the fourth quarter valued at about $142,000. Finally, Boxer Capital LLC acquired a new stake in shares of Disc Medicine Opco in the fourth quarter valued at about $176,000. 75.42% of the stock is owned by institutional investors and hedge funds.

Disc Medicine Opco Company Profile

(Get Rating)

Disc Medicine, Inc, a clinical-stage biotechnology company, engages in discovering, developing, and commercializing novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis.